Activity and Safety of Atezolizumab Combined with Carboplatin and Pemetrexed in Patients with Untreated Brain Metastases from Non-squamous NSCLC
Findings from the Atezo-Brain study
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Findings from the Atezo-Brain study
Findings from the MEDITREME study
Findings from the registrational phase II MagnetisMM-3 study
Evidence for efficacy is based on the results from the MAGNITUDE study
New indication concerns the combination first-line treatment for locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma
Findings from the INHERIT study
Findings from the LUMINA study
Findings from the PANDA study
Evidence for efficacy is based on the results from the SUNLIGHT study
It is indicated for the treatment of adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy
Findings from the longest follow-up of a neoadjuvant study in this setting
Findings from the GLOW study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.